Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/14833
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRoth, VR-
dc.contributor.authorLongpre, T-
dc.contributor.authorCoyle, D-
dc.contributor.authorSuh, KN-
dc.contributor.authorTaljaard, M-
dc.contributor.authorMuldoon, KA-
dc.contributor.authorRamotar, K-
dc.contributor.authorForster, A-
dc.date.accessioned2017-06-28T12:37:35Z-
dc.date.available2016-07-27-
dc.date.available2017-06-28T12:37:35Z-
dc.date.issued2016-
dc.identifier.citationPLOS ONE, 2016en_US
dc.identifier.issnhttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000381515900045&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=f12c8c83318cf2733e615e54d9ed7ad5-
dc.identifier.issnARTN e0159667-
dc.identifier.issnhttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000381515900045&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=f12c8c83318cf2733e615e54d9ed7ad5-
dc.identifier.issnARTN e0159667-
dc.identifier.issn1932-6203-
dc.identifier.urihttp://bura.brunel.ac.uk/handle/2438/14833-
dc.description.abstractBackground The literature remains conflicted regarding the most effective way to screen for MRSA. This study was designed to assess costs associated with universal versus risk factor-based screening for the reduction of nosocomial MRSA transmission. Methods The study was conducted at The Ottawa Hospital, a large multi-centre tertiary care facility with approximately 47,000 admissions annually. From January 2006-December 2007, patients underwent risk factor-based screening for MRSA on admission. From January 2008 to August 2009 universal MRSA screening was implemented. A comparison of costs incurred during risk factor-based screening and universal screening was conducted. The model incorporated probabilities relating to the likelihood of being tested and the results of polymerase chain reaction (PCR) testing with associated effects in terms of MRSA bacteremia and true positive and negative test results. Inputted costs included laboratory testing, contact precautions and infection control, private room costs, housekeeping, and length of hospital stay. Deterministic sensitivity analyses were conducted. Results The risk factor-based MRSA screening program screened approximately 30% of admitted patients and cost the hospital over $780 000 annually. The universal screening program screened approximately 83% of admitted patients and cost over $1.94 million dollars, representing an excess cost of $1.16 million per year. The estimated additional cost per patient screened was $17.76.en_US
dc.format.extent? - ? (16)-
dc.languageEnglish-
dc.language.isoenen_US
dc.publisherPUBLIC LIBRARY SCIENCEen_US
dc.subjectScience & Technologyen_US
dc.subjectMultidisciplinary Sciencesen_US
dc.subjectScience & Technology - Other Topicsen_US
dc.subjectNOSOCOMIAL TRANSMISSIONen_US
dc.subjectDECISION-ANALYSISen_US
dc.subjectADMISSIONen_US
dc.subjectINFECTIONen_US
dc.subjectCARRIAGEen_US
dc.subjectMULTICENTERen_US
dc.subjectPERSPECTIVEen_US
dc.subjectSTRATEGIESen_US
dc.subjectCARRIERSen_US
dc.subjectSURGERYen_US
dc.titleCost Analysis of Universal Screening vs. Risk Factor-Based Screening for Methicillin-Resistant Staphylococcus aureus (MRSA)en_US
dc.typeArticleen_US
dc.identifier.doihttp://dx.doi.org/10.1371/journal.pone.0159667-
dc.relation.isPartOfPLOS ONE-
pubs.issue7-
pubs.publication-statusPublished-
pubs.volume11-
Appears in Collections:Dept of Clinical Sciences Research Papers

Files in This Item:
File Description SizeFormat 
Fulltext.pdf451.37 kBAdobe PDFView/Open


Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.